JPWO2019152715A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019152715A5
JPWO2019152715A5 JP2020541805A JP2020541805A JPWO2019152715A5 JP WO2019152715 A5 JPWO2019152715 A5 JP WO2019152715A5 JP 2020541805 A JP2020541805 A JP 2020541805A JP 2020541805 A JP2020541805 A JP 2020541805A JP WO2019152715 A5 JPWO2019152715 A5 JP WO2019152715A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513329A (ja
JP7268038B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016156 external-priority patent/WO2019152715A1/en
Publication of JP2021513329A publication Critical patent/JP2021513329A/ja
Publication of JPWO2019152715A5 publication Critical patent/JPWO2019152715A5/ja
Priority to JP2023068910A priority Critical patent/JP7486636B2/ja
Application granted granted Critical
Publication of JP7268038B2 publication Critical patent/JP7268038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541805A 2018-01-31 2019-01-31 抗ｍｓ４ａ４ａ抗体及びその使用方法 Active JP7268038B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023068910A JP7486636B2 (ja) 2018-01-31 2023-04-20 抗ｍｓ４ａ４ａ抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862624600P 2018-01-31 2018-01-31
US62/624,600 2018-01-31
US201862783096P 2018-12-20 2018-12-20
US62/783,096 2018-12-20
PCT/US2019/016156 WO2019152715A1 (en) 2018-01-31 2019-01-31 Anti-ms4a4a antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023068910A Division JP7486636B2 (ja) 2018-01-31 2023-04-20 抗ｍｓ４ａ４ａ抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021513329A JP2021513329A (ja) 2021-05-27
JPWO2019152715A5 true JPWO2019152715A5 (zh) 2022-02-07
JP7268038B2 JP7268038B2 (ja) 2023-05-02

Family

ID=65444352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541805A Active JP7268038B2 (ja) 2018-01-31 2019-01-31 抗ｍｓ４ａ４ａ抗体及びその使用方法
JP2023068910A Active JP7486636B2 (ja) 2018-01-31 2023-04-20 抗ｍｓ４ａ４ａ抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023068910A Active JP7486636B2 (ja) 2018-01-31 2023-04-20 抗ｍｓ４ａ４ａ抗体及びその使用方法

Country Status (5)

Country Link
US (3) US11472874B2 (zh)
EP (1) EP3746476A1 (zh)
JP (2) JP7268038B2 (zh)
CN (1) CN111971301A (zh)
WO (1) WO2019152715A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
WO2021022083A2 (en) 2019-07-31 2021-02-04 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
WO2023114499A1 (en) 2021-12-17 2023-06-22 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
JP7452918B2 (ja) 2021-12-22 2024-03-19 国立大学法人 鹿児島大学 マクロファージの製造方法、分化誘導剤、分化誘導キット、マクロファージの分化誘導方法、マクロファージの増殖促進剤、マクロファージの増殖促進キット、マクロファージの増殖方法及びマクロファージ
WO2024026509A2 (en) * 2022-07-29 2024-02-01 Anavex Life Sciences Corp. Therapy selection and treatment of neurodegenerative disorders
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
AU2002251692A1 (en) * 2000-12-08 2002-08-19 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US8026054B2 (en) 2004-06-14 2011-09-27 The Board Of Trustees Of The University Of Illinois Antibodies against cells of fetal origin
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
EP2390349A1 (en) 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
JP6339015B2 (ja) 2011-08-23 2018-06-06 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
CN104774264B (zh) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20190321443A1 (en) * 2016-02-16 2019-10-24 President And Fellows Of Harvard College Modulators of MS4A activity
CN105759057A (zh) 2016-04-12 2016-07-13 上海凯璟生物科技有限公司 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
CN112204050A (zh) 2018-01-31 2021-01-08 艾莱克特有限责任公司 抗ms4a6a抗体及其使用方法
WO2021022083A2 (en) 2019-07-31 2021-02-04 Alector Llc Anti-ms4a4a antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2020533948A5 (zh)
JP2020532947A5 (zh)
AU2014342103A1 (en) Specific anti-CD38 antibodies for treating human cancers
JP7363828B2 (ja) 二重特異性抗体
JP7476997B2 (ja) 二重特異性抗体
US20230048260A1 (en) Therapeutic anti-cd40 ligand antibodies
EP4228693A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
JPWO2019152715A5 (zh)
US20220089736A1 (en) Immune targeting molecules and uses thereof
US10072081B2 (en) Anti-CTLA4, anti-GLUT2 protein for the treatment of type 1 diabetes
WO2020204152A1 (ja) 二重特異性抗体
JPWO2020014617A5 (zh)
WO2021020416A1 (ja) 二重特異性抗体
JPWO2021022083A5 (zh)
JPWO2019152706A5 (zh)
US20240084026A1 (en) Anti-4-1bb antibodies and methods of making and using thereof
RU2783619C2 (ru) Молекулы, связывающие adam9, и способы их применения
JPWO2020023920A5 (zh)
JP2022060182A (ja) 二重特異性抗体を有効成分として含む医薬組成物
IL304898A (en) New anti-CD24 antibodies